Literature DB >> 27480858

In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species.

David R Snydman1, Nilda V Jacobus2, Laura A McDermott2.   

Abstract

We evaluated the in vitro activity of imipenem-relebactam (imipenem-MK7655) against 451 recent clinical isolates within the Bacteroides group and related species. Relebactam did not enhance or inhibit the activity of imipenem against Bacteroides fragilis or other Bacteroides species. No synergistic or antagonistic effect was observed. The MICs of imipenem-relebactam were equal to or within one dilution of the MICs of these isolates to imipenem.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27480858      PMCID： PMC5038300          DOI： 10.1128/AAC.01125-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).

Authors:  Mariana Castanheira; Rodrigo E Mendes; Leah N Woosley; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2011-03-18       Impact factor: 5.790

2.  Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Authors:  D R Snydman; N V Jacobus; L A McDermott; Y Golan; E J C Goldstein; L Harrell; S Jenkins; D Newton; C Pierson; J Rosenblatt; R Venezia; S L Gorbach; A M Queenan; D W Hecht
Journal:  Anaerobe       Date:  2011-06-02       Impact factor: 3.331

3.  In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.

Authors:  Elizabeth B Hirsch; Kimberly R Ledesma; Kai-Tai Chang; Michael S Schwartz; Mary R Motyl; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

4.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

5.  Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott; Yoav Golan; David W Hecht; Ellie J C Goldstein; Lizzie Harrell; Stephen Jenkins; Duane Newton; Carl Pierson; John D Rihs; Victor L Yu; Richard Venezia; Sydney M Finegold; Jon E Rosenblatt; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079
  5 in total
  6 in total

Review 1.  Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Authors:  George G Zhanel; Courtney K Lawrence; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Michael Zhanel; Philippe R S Lagacé-Wiens; Andrew Walkty; Andrew Denisuik; Alyssa Golden; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

Review 2.  Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.

Authors:  Darren Wong; David van Duin
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 3.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

4.  Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.

Authors:  Ellie J C Goldstein; Diane M Citron; Kerin L Tyrrell; Eliza Leoncio; C Vreni Merriam
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo.

Authors:  Bassam El Hafi; Sari S Rasheed; Antoine G Abou Fayad; George F Araj; Ghassan M Matar
Journal:  Front Microbiol       Date:  2019-04-30       Impact factor: 5.640

Review 6.  A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Authors:  Toni A Campanella; Jason C Gallagher
Journal:  Infect Drug Resist       Date:  2020-11-25       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.